No title
For Alligator Bioscience AB, a company developing immunotherapeutic antibodies, it is crucial to efficiently evaluate a large number of potential drug candidates at an early stage. The in-house developed RUBYTM concept, combining monoclonal antibodies into bispecific antibodies without lead optimization, requires implementation of high-throughput technologies. Restriction enzyme digestion, used fo
